nach oben

Supportive Care in Cancer

Erschienen in:

01.06.2006 | Review Article

Anti-inflammatory agents in the management of alimentary mucositis

Erschienen in: Supportive Care in Cancer | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

Background

Alimentary mucositis is a significant complication of cancer therapy, with important clinical and economic implications.

Materials and methods

In June 2005, the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology conducted an evidence-based review of the literature on alimentary mucositis. The goal of this literature review was to update previously published guidelines for the management of mucositis.

Results

This article reports the findings of the subgroup charged with reviewing the literature related to anti-inflammatory interventions. Considerable preclinical and clinical evidence suggests that the use of anti-inflammatory agents may be a promising approach to reduce the severity of mucositis. However, there was not enough evidence to support any new guidelines advocating the use of any specific anti-inflammatory intervention.

Conclusion

Thus, there is a need for well-designed clinical trials evaluating the use of anti-inflammatory agents in the management of mucositis.

Abdelaal AS, Barker DS, Fergusson MM (1989) Treatment for irradiation-induced mucositis. Lancet 1:97CrossRefPubMed

Baughan CA, Canney PA, Buchanan RB et al (1993) A randomized trial to assess the efficacy of 5-aminosalicylic acid for the prevention of radiation enteritis. Clin Oncol (R Coll Radiol) 5:19–24

Diaz A, Chepenik KP, Korn JH et al (1998) Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Exp Cell Res 241:222–229CrossRefPubMed

Duenas-Gonzalez A, Sobrevilla-Calvo P, Frias-Mendivil M et al (1996) Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. Bone Marrow Transplant 17:809–812PubMed

Elting LS, Cooksley C, Chambers M et al (2003) The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98:1531–1539CrossRefPubMed

Epstein JB, Stevenson-Moore P (1986) Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy. Oral Surg Oral Med Oral Pathol 62:145–148CrossRefPubMed

Epstein JB, Stevenson-Moore P, Jackson S et al (1989) Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse. Int J Radiat Oncol Biol Phys 16:1571–1575PubMed

Epstein JB, Gorsky M, Guglietta A et al (2000) The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer 89:2258–2265CrossRefPubMed

Epstein JB, Silverman S Jr, Paggiarino DA et al (2001) Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo- controlled clinical trial. Cancer 92:875–885CrossRefPubMed

10.

Gibson RJ, Keefe DM, Thompson FM et al (2002) Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 47:2751–2757CrossRefPubMed

11.

Hadorn DC, Baker D, Hodges JS et al (1996) Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 49:749–754CrossRefPubMed

12.

Hall PD, Benko H, Hogan KR et al (1995) The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp Hematol 23:1256–1260PubMed

13.

Hanson WR, Marks JE, Reddy SP et al (1995) Protection from radiation-induced oral mucositis by misoprostol, a prostaglandin E(1) analog: a placebo-controlled, double-blind clinical trial. Am J Ther 2:850–857PubMedCrossRef

14.

Hong JH, Chiang CS, Tsao CY et al (1999) Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol 75:1421–1427CrossRefPubMed

15.

Johnson DJ, Scott CB, Marks JE et al (2002) Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07). Int J Radiat Oncol Biol Phys 54:1455–1459CrossRefPubMed

16.

Khan AM, Birk JW, Anderson JC et al (2000) A prospective randomized placebo-controlled double-blinded pilot study of misoprostol rectal suppositories in the prevention of acute and chronic radiation proctitis symptoms in prostate cancer patients. Am J Gastroenterol 95:1961–1966CrossRefPubMed

17.

Labar B, Mrsic M, Pavletic Z et al (1993) Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant 11:379–382PubMed

18.

Lalla RV, Peterson DE (2005) Oral mucositis. Dent Clin North Am 49:167–184CrossRefPubMed

19.

Leborgne JH, Leborgne F, Zubizarreta E et al (1998) Corticosteroids and radiation mucositis in head and neck cancer. A double-blind placebo-controlled randomized trial. Radiother Oncol 47:145–148CrossRefPubMed

20.

Martenson JA Jr, Hyland G, Moertel CG et al (1996) Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial. Int J Radiat Oncol Biol Phys 35:299–303CrossRefPubMed

21.

Matejka M, Nell A, Kment G et al (1990) Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. Br J Oral Maxillofac Surg 28:89–91CrossRefPubMed

22.

Miyazono Y, Gao F, Horie T (2004) Oxidative stress contributes to methotrexate-induced small intestinal toxicity in rats. Scand J Gastroenterol 39:1119–1127CrossRefPubMed

23.

Montecucco C, Caporali R, Rossi S et al (1994) Allopurinol mouthwashes in methotrexate-induced stomatitis. Arthritis Rheum 37:777–778PubMedCrossRef

24.

Nicolopoulos N, Mantidis A, Stathopoulos E et al (1985) Prophylactic administration of indomethacin for irradiation esophagitis. Radiother Oncol 3:23–25PubMedCrossRef

25.

Northway MG, Libshitz HI, Osborne BM et al (1980) Radiation esophagitis in the opossum: radioprotection with indomethacin. Gastroenterology 78:883–892PubMed

26.

Northway MG, Eastwood GL, Libshitz HI et al (1982) Antiinflammatory agents protect opossum esophagus during radiotherapy. Dig Dis Sci 27:923–928CrossRefPubMed

27.

Pillsbury HC 3rd, Webster WP, Rosenman J (1986) Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Arch Otolaryngol Head Neck Surg 112:552–553PubMed

28.

Porta C, Moroni M, Nastasi G (1994) Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis. Am J Clin Oncol 17:246–247PubMedCrossRef

29.

Porteder H, Rausch E, Kment G et al (1988) Local prostaglandin E2 in patients with oral malignancies undergoing chemo- and radiotherapy. J Craniomaxillofac Surg 16:371–374PubMed

30.

Raber-Durlacher J, Barasch A, Peterson DE et al (2004) Oral complications and management considerations in patients treated with high-dose cancer chemotherapy. Supportive Cancer Therapy 1:219–229PubMedCrossRef

31.

Resbeut M, Marteau P, Cowen D et al (1997) A randomized double blind placebo controlled multicenter study of mesalazine for the prevention of acute radiation enteritis. Radiother Oncol 44:59–63CrossRefPubMed

32.

Rothwell BR, Spektor WS (1990) Palliation of radiation-related mucositis. Spec Care Dentist 10:21–25PubMedCrossRef

33.

Rubenstein EB, Peterson DE, Schubert M et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026–2046CrossRefPubMed

34.

RxKinetix, Inc., Louisville, CO (2005) RxKinetix sucessfully concludes its phase 2 trial in oral mucositis. http://www.rxkinetix.com. Cited 18 Oct 2005

35.

Rymes N, Glick L, Holmes JA (1996) Topical mesalazine in the treatment of chemotherapy and radiotherapy-induced oral mucositis. Bone Marrow Transplant 18:484PubMed

36.

Sironi M, Pozzi P, Polentarutti N et al (1996) Inhibition of inflammatory cytokine production and protection against endotoxin toxicity by benzydamine. Cytokine 8:710–716CrossRefPubMed

37.

Somerfield MR, Padberg JR, Pfister DG et al (2000) ASCO clinical practice guidelines: process, progress, pitfalls, and prospects. Classic Papers and Current Comments 4:881–886

38.

Sonis ST (1998) Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34:39–43CrossRefPubMed

39.

Sonis ST, Peterson RL, Edwards LJ et al (2000) Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 36:373–381CrossRefPubMed

40.

Sonis ST, O’Donnell KE, Rishi P et al (2003) Inhibition of ceramide synthase, but not sphingomyelinase, attenuates radiation-induced mucositis in hamsters. Proc Am Soc Clin Oncol 22:747 (Abstract 3005)

41.

Sonis ST, Elting LS, Keefe D et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995–2025CrossRefPubMed

42.

Sonis ST, O’Donnell KE, Popat R et al (2004) The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol 40:170–176CrossRefPubMed

43.

Stokman MA, Spijkervet FK, Burlage FR et al (2005) Clinical effects of flurbiprofen tooth patch on radiation-induced oral mucositis. A pilot study. Support Care Cancer 13:42–48CrossRefPubMed

44.

Tanner NS, Stamford IF, Bennett A (1981) Plasma prostaglandins in mucositis due to radiotherapy and chemotherapy for head and neck cancer. Br J Cancer 43:767–771PubMed

45.

Tochner Z, Barnes M, Mitchell JB et al (1990) Protection by indomethacin against acute radiation esophagitis. Digestion 47:81–87PubMedCrossRef

46.

Trotti A, Bellm LA, Epstein JB et al (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66:253–262CrossRefPubMed

47.

Valencia J, Velilla C, Urpegui A et al (2002) The efficacy of orgotein in the treatment of acute toxicity due to radiotherapy on head and neck tumors. Tumori 88:385–389PubMed

48.

van’t Land B, van Beek NM, van den Berg JJ et al (2004) Lactoferrin reduces methotrexate-induced small intestinal damage, possibly through inhibition of GLP-2-mediated epithelial cell proliferation. Dig Dis Sci 49:425–433CrossRefPubMed

49.

Wolff JE, Hauch H, Kuhl J et al (1998) Dexamethasone increases hepatotoxicity of MTX in children with brain tumors. Anticancer Res 18:2895–2899PubMed

50.

Xian CJ, Cool JC, Howarth GS et al (2002) Effects of TGF-alpha gene knockout on epithelial cell kinetics and repair of methotrexate-induced damage in mouse small intestine. J Cell Physiol 191:105–115CrossRefPubMed

51.

Xun CQ, Thompson JS, Jennings CD et al (1994) Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2- incompatible transplanted SCID mice. Blood 83:2360–2367PubMed

52.

Yeoh AS, Bowen JM, Gibson RJ et al (2005) Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys

53.

Yokomizo H, Yoshimatsu K, Hashimoto M et al (2004) Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis. Anticancer Res 24:1131–1134PubMed

54.

Yoshida T, Hirakata M (2003) Therapeutic benefits of irsogladine maleate on aphthous stomatitis induced by methotrexate in rheumatoid arthritis. J Rheumatol 30:2082–2083PubMed

Titel: Anti-inflammatory agents in the management of alimentary mucositis
Publikationsdatum: 01.06.2006
Erschienen in: Supportive Care in Cancer / Ausgabe 6/2006
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-006-0050-9

Springer Medizin

Anti-inflammatory agents in the management of alimentary mucositis

Abstract

Background

Materials and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2006

Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis

Abstracts

New thoughts on the pathobiology of regimen-related mucosal injury

Alimentary tract mucositis in cancer patients: impact of terminology and assessment on research and clinical practice

Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience

Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie